3LAQ

Structure-based engineering of species selectivity in the uPA-uPAR interaction


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.341 
  • R-Value Work: 0.231 
  • R-Value Observed: 0.237 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.

Lin, L.Gardsvoll, H.Huai, Q.Huang, M.Ploug, M.

(2010) J Biol Chem 285: 10982-10992

  • DOI: 10.1074/jbc.M109.093492
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glycolipid-anchored receptor (uPAR) is decisive for cell surface-associated plasminogen activation. Because plasmin activity controls fibrinolysis in a varie ...

    The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glycolipid-anchored receptor (uPAR) is decisive for cell surface-associated plasminogen activation. Because plasmin activity controls fibrinolysis in a variety of pathological conditions, including cancer and wound healing, several intervention studies have focused on targeting the uPA.uPAR interaction in vivo. Evaluations of such studies in xenotransplanted tumor models are, however, complicated by the pronounced species selectivity in this interaction. We now report the molecular basis underlying this difference by solving the crystal structure for the murine uPA.uPAR complex and demonstrate by extensive surface plasmon resonance studies that the kinetic rate constants for this interaction can be swapped completely between these orthologs by exchanging only two residues. This study not only discloses the structural basis required for a successful rational design of the species selectivity in the uPA.uPAR interaction, which is highly relevant for functional studies in mouse models, but it also suggests the possible development of general inhibitors that will target the uPA.uPAR interaction across species barriers.


    Organizational Affiliation

    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Urokinase plasminogen activator surface receptor
U, V
277Mus musculusMutation(s): 0 
Gene Names: Plaur
Find proteins for P35456 (Mus musculus)
Go to UniProtKB:  P35456
NIH Common Fund Data Resources
IMPC  MGI:97612
Protein Feature View
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Urokinase-type plasminogen activator
A, B
134Mus musculusMutation(s): 0 
Gene Names: Plau
EC: 3.4.21.73
Find proteins for P06869 (Mus musculus)
Go to UniProtKB:  P06869
NIH Common Fund Data Resources
IMPC  MGI:97611
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NAG
Query on NAG

Download CCD File 
U, V
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.341 
  • R-Value Work: 0.231 
  • R-Value Observed: 0.237 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.421α = 90
b = 137.248β = 106.17
c = 65.785γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
AMoREphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2010-01-06 
  • Released Date: 2010-02-02 
  • Deposition Author(s): Huang, M.

Revision History 

  • Version 1.0: 2010-02-02
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Advisory, Refinement description, Version format compliance